Helsinn Therapeutics (U.S.) Inc., Signs Co-Promotion Agreement for Cancer Therapeutic Zykadia® in the US

5 September 2017

AMAL Therapeutics raises €8 million (CHF 8.8 million) in first closing of Series B financing round

5 September 2017

Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

2 August 2017

XADAGO® (SAFINAMIDE) NOW AVAILABLE IN THE U.S. FOR PARKINSON’S DISEASE PATIENTS

11 July 2017

HELSINN ADVANCED SYNTHESIS S.A. BIASCA: CONCORSO PER L’ASSEGNAZIONE DI BORSE DI STUDIO 2017/2018

7 July 2017

Sondaggio FIT 2019

23 June 2017

Healthcare Life Sciences & Review dedicates an article to FIT

21 June 2017

Helsinn Group Announces Upcoming Presentation of Phase III data in NEPA (netupitant/palonestron) at MASCC/ISOO Congress in Washington DC

20 June 2017

Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome

14 June 2017

37a Assemblea generale ordinaria di FIT

9 June 2017